60 results about "CD79B" patented technology

The invention relates to the technical field of gene engineering, in particular to two cynoglossus semilaevis vibriosis-resistant genes and an application method thereof. According to the invention, the effects of the CD79a and the CD79b in the cynoglossus semilaevis in resisting vibriosis are mainly studied, verification is respectively carried out in vivo and in vitro, the process of disease-resistant breeding of the cynoglossus semilaevis is further promoted, and it is indicated that the CD79a and the CD79b have the effect of inhibiting vibrio harveyi.

Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided CD79b-specific antibodies or antigen-binding fragments, cells expressing the provided CD79b-specific antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled CD79b-specific antibodies or antigen-binding fragments. In addition, methods of producing and using the provided CD79b-specific antibodies and antigen-binding fragments are described.

To identify gene mutations in MYD88 and / or CD79B simultaneously.SOLUTION: The present invention comprises: a primer set for MYD88 gene mutations, and a primer set for CD79B gene mutations; as well as a mutant-type probe for MYD88 gene, a wild-type probe for MYD88 gene, a mutant-type probe for CD79B gene, and a wild-type probe for CD79B gene.SELECTED DRAWING: None

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and / or NK cells, in shorter times than previously and / or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, P13, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM 23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

An anti-CD79B protein monoclonal antibody and related products and uses thereof are disclosed. The anti-CD79B protein monoclonal antibody comprises a heavy chain and a light chain, wherein the heavy chain includes a heavy chain variable region, and the light chain includes a light chain variable region. The heavy chain variable region includes complementary-determining regions CDR1, CDR2, and CDR3 with amino acid sequences as shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively. The light chain variable region comprises complementary-determining regions CDR1, CDR2, and CDR3 with amino acid sequences as shown in SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, respectively. The anti-CD79B protein monoclonal antibody exhibits high specificity and sensitivity, enabling specific recognition of cells expressing CD79B protein. It is suitable for immunological detection, and effectively prevents false-positive and false-negative results in immunological assays, thereby further improving the accuracy of detection and diagnostic outcomes.

The invention relates to the technical field of adoptive immunotherapy, in particular to a double-target CD19 / CD79b CAR structure and application thereof. The structure comprises a Loop CAR structure or a tan CAR structure, and the Loop CAR structure or the tan CAR structure comprises a signal peptide sequence, an antigen binding structural domain, a connecting peptide, an antigen binding structural domain, a hinge region, a transmembrane structural domain, a costimulatory signal molecule and a cytoplasm signal transduction sequence which are connected in sequence; the antigen binding structural domain is an independent scFV structure aiming at specific targets, and the specific targets comprise CD19 and CD79b. The structure can be applied to immune cells, nucleic acid molecules and carriers. The structure can improve the killing effect.

This article provides a CD79b antibody and a CD79b-specific chimeric antigen receptor (CAR). Further, this article provides immune cells expressing the CD79b-specific CAR and a method for treating cancer by administering the CD79b-specific CAR immune cells.

The present invention relates to humanized antibodies or target-binding fragments or derivatives thereof that retain target-binding ability, which bind to human CD79b (Figure 1).

The present invention relates to the field of biomedicine, and in particular, to a bispecific antibody comprising a first antigen-binding domain that specifically binds to a first antigen and a second antigen-binding domain that specifically binds to a second antigen, wherein the first antigen is CD79b and the second antigen is not CD79b. The present invention also relates to nucleic acid molecules, vectors and host cells encoding the bispecific antibody, derivatives of the bispecific antibody, and their use in treating diseases.

The invention discloses a gene marker panel for diagnosing PCNSL based on cerebrospinal fluid ctDNA, and relates to the technical field of gene detection, the technical key point is that the gene marker panel comprises MYD88, PIM1, CD79B, GNA13, IRF4, DTX1, KMT2D and B2M genes, and PCNSL diagnosis and prognosis evaluation are realized through targeted capture sequencing and a machine learning model. The specificity of the kit in MYD88 wild type PCNSL cases reaches 100%, the BTK inhibitor treatment response and the total lifetime of patients can be predicted, tiny residual focuses can be detected, and recurrence can be warned in advance. The invention further provides a detection kit, a prognosis evaluation system and online webpage application, the quantity demanded of samples is small, the detection sensitivity is high, the specificity is high, and a powerful tool is provided for PCNSL diagnosis and treatment.

The invention relates to the field of biological medicine, in particular to pharmaceutical application of a bispecific antibody, and the medicine is used for preventing and / or treating B cell lymphoma related diseases, inflammatory diseases and / or autoimmune diseases in subjects. The bispecific antibody comprises a first antigen binding domain specifically bound with a first antigen and a second antigen binding domain specifically bound with a second antigen, the first antigen is CD79b, and the second antigen is not CD79b.

The disclosure relates to a multispecific (e.g., bispecific) antibody, which includes a first antigen-binding domain that specifically binds to a first antigen and a second antigen-binding domain that specifically binds to a second antigen. The first antigen is CD79b and the second antigen is not CD79b. The disclosure also relates to nucleic acid molecules, vectors and host cells encoding the bispecific antibodies, derivatives of the bispecific antibodies, and their use for disease treatment.

The invention relates to a molecular marker for immunotherapy prediction of a targeting shower cell and application of the molecular marker, and belongs to the technical field of molecular biology. The invention provides a molecular marker for immunotherapy prediction of a targeting shower cell. The molecular marker comprises CD8, CD4, PD-1, Foxp3, CD19 and CD3, wherein the CD8, the CD4, the PD-1, the Foxp3, the CD19 and the CD3 are used for immunotherapy prediction; or comprises a CD45, a CD45RA, a CD45RO, a CD25, a CCR7 and a CD127; or comprises CD3, LAG3, Tim3, ICOS, CD69 and CD103; or comprises a CD79A, a CD79B, a CD20, a CD21 and a CD138; or the CD56, the CD161, the CD57, the CD94 and the Granzyme B are included; the invention relates to a CD56, CD161, CD57, CD94 and Granzyme B. The CD56, the CD161, the CD57, the CD94 and the Granzyme B. The molecular marker can accurately distinguish shower cell groups and interaction.

The invention discloses a multiplex fluorescence immunohistochemical detection kit for rare lymphoma and application of the multiplex fluorescence immunohistochemical detection kit. The multiplex fluorescence immunohistochemical detection kit for rare lymphoma comprises a primary antibody reagent and a fluorescence staining reagent, the primary antibody reagent is prepared from a rabbit anti-human CD15 monoclonal antibody, a rabbit anti-human CD30 monoclonal antibody, a KI-67 monoclonal antibody, a rabbit anti-human CD79b monoclonal antibody, a rabbit anti-human CD3 monoclonal antibody and a rabbit anti-human CD20 monoclonal antibody. When the multiplex fluorescence immunohistochemical detection kit for the rare lymphoma is used, a false positive result caused by channel spectrum crosstalk is avoided to the greatest extent through a specific staining sequence of each target protein and fluorescein matching, and the purpose of detecting the rare lymphoma, especially the rare type of lymphoma, is achieved. The kit can be used for synchronous detection of lymphoma, such as hodgkin lymphoma, mantle cell lymphoma and marginal region lymphoma, and provides a reliable basis for lymphoma immune targeted therapy.

Disclosed are biomarker-based methods of treatment, monitoring, and diagnosis for IL-17 dependent conditions, including hidradenitis suppurativa. The biomarker may be selected from the group consisting of IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, kits for measuring biomarkers, diagnosing and treating IL-17 dependent conditions, and identifying superresponders are also disclosed.

The present application relates to the technical field of multi-gene detection, and in particular to a set of capture probes for follicular lymphoma multi-gene detection, a kit and a detection analysis method ARID1A, ARID1B, ATM, ATP6V1B2, B2M, BCL10, BCL2, BCL6, BCL7A, BTG1, BTG2, BTK, CARD11, CCND3, CD58, CD70, CD79A, CD79B, CDK4, CDKN2A The capture probe set comprises capture probes for specifically binding to 74 follicular lymphoma related genes, and the capture probe set preferably comprises nucleotides with sequences as shown in SEQ ID NO. 1-937. The probe set of the present application can realize one-time detection of variation in the full exon region of 74 follicular lymphoma related genes in the sample to be detected in the same system, has high specificity, high average sequencing depth and wide coverage area.

Provided are novel bifunctional conjugates, especially degrader-antibody conjugates (DACs), that are useful in meditation the levels of target proteins and treating certain diseases. A conjugate disclosed herein comprises a binding moiety that specifically binds to a binding protein such as GPRC5D, CD79b or CD19, an optional linker, and payload degrader, such as a payload derived from a PROTAC molecule, which is a bioactive moiety capable of inducing degradation of a target protein, such as one or more of the Ikaros ('IKZF') family.

The invention belongs to the technical field of biomedicine, and relates to a biomarker for diagnosing blood stasis syndrome of ischemic heart failure and application of the biomarker. The biomarker for diagnosing the blood stasis syndrome of the ischemic heart failure, provided by the invention, is at least one of a gene marker and a protein marker; wherein the gene marker is at least one of CD19, CD22, CD79A, CD79B and CR2, and the gene marker is at least one of CD19, CD22, CD79A, CD79B and CR2; the protein marker is at least one of F2, F8, F9 and FN1. The invention also provides a product for diagnosing the blood stasis syndrome of the ischemic heart failure. The kit contains a reagent for detecting the gene marker or / and the protein marker. By detecting the expression level of the biomarker in the blood of a patient with the ischemic heart failure blood stasis syndrome, the patient with the ischemic heart failure blood stasis syndrome and a healthy control can be effectively diagnosed and distinguished, and auxiliary diagnosis of the ischemic heart failure blood stasis syndrome is achieved.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM 23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

The present application relates to the technical field of genetic engineering, in particular to two Cynoglossus semilaevis anti-vibrio disease genes and application methods. The present application mainly studies the role of CD79a and CD79b in Cynoglossus semilaevis in resisting vibrio disease, and verifies from two directions of in vivo and in vitro, further promotes the progress of Cynoglossus semilaevis disease resistance breeding, and shows that CD79a and CD79b have the role of inhibiting Vibrio harveyi.

The invention relates to an anti-CD79B protein monoclonal antibody and a related product and application thereof, and belongs to the technical field of biological medicine, the anti-CD79B protein monoclonal antibody comprises a heavy chain and a light chain, the heavy chain comprises a heavy chain variable region; the light chain comprises a light chain variable region, and amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are respectively as shown in SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11; the antibody has high specificity and sensitivity, can specifically recognize cells expressing CD79B protein, is not only suitable for immunological detection, but also can effectively prevent false positive and false negative phenomena in immunological detection, and is beneficial to further improving the accuracy of detection and diagnosis results.

The present disclosure relates to antibodies and antibody-drug conjugates (ADCs) targeting CD79b and / or CD20 and compositions containing the antibodies or ADCs and therapeutic applications thereof.

This invention discloses a gene biomarker panel for detecting PCNSL based on cerebrospinal fluid (cerebrospinal fluid) ctDNA, relating to the fields of gene detection and molecular diagnostics. The gene biomarker panel includes MYD88, PIM1, CD79B, GNA13, IRF4, DTX1, KMT2D, and B2M. By detecting the mutation status of these genes in a subject's cerebrospinal fluid sample, the mutation status is input into a trained random forest classification model to generate auxiliary judgment results, providing molecular evidence for diagnosing PCNSL in the subject. This eight-gene combination panel has shown high diagnostic specificity in multiple cerebrospinal fluid ctDNA-based validation cohorts and has the ability to identify MYD88 wild-type PCNSL.

Provided are an anti-CD79B antibody-drug conjugate, and a preparation method therefor and pharmaceutical use thereof. In particular, provided are an antibody-drug conjugate (ADC) which comprises an anti-CD79B antibody conjugated with an MMAE or a derivative thereof, exatecan or a derivative thereof, or Eribulin or a derivative thereof, a pharmaceutical composition containing the ADC, and use thereof in preparation of a drug for treatment of a CD79B-mediated disease or disorder, especially use thereof in preparation of an anti-cancer drug.

The present invention provides a bispecific antibody targeting CD3 and CD79b and its use. The antibody comprises a first antigen-binding region with CD3 binding activity and a second antigen-binding region with CD79b binding activity. The first antigen-binding region is selected from a CD3 single-chain antibody, and the second antigen-binding region comprises a CD79b heavy chain and a CD79b light chain. This antibody can simultaneously bind to CD79b-positive tumor cells and T cells, effectively mediating T cell killing of tumor cells and effectively treating cancer.

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

The present invention provides therapeutics for Non-Hodgkin Lymphoma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target CD79b.